Healthy Living

Genetics On the Forefront of New Cystic Fibrosis Treatment

Ivacaftor's immense potential

Now that ivacaftor is on the market both in the United States and European Union, researchers are continuing to gather data on its effectivity in the CF population. Results are showing that the medication is still showing increased FEV rates and better clinical outcomes among patients using the drug. Since it has only been on the market in the states since 2014, long-term outcomes are still uncertain.